Harvard Bioscience (NASDAQ:HBIO) Price Target Cut to $3.00 by Analysts at Benchmark

Harvard Bioscience (NASDAQ:HBIO) had its target price decreased by Benchmark from $4.50 to $3.00 in a research report released on Tuesday,Benzinga reports. Benchmark currently has a speculative buy rating on the medical instruments supplier’s stock.

Several other brokerages have also weighed in on HBIO. KeyCorp reaffirmed a “sector weight” rating on shares of Harvard Bioscience in a research note on Wednesday, April 9th. StockNews.com initiated coverage on shares of Harvard Bioscience in a research note on Tuesday, May 6th. They set a “hold” rating for the company.

Harvard Bioscience Trading Up 5.3%

Shares of HBIO stock opened at $0.37 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91. The firm has a market cap of $16.39 million, a PE ratio of -1.12 and a beta of 1.44. The company has a 50-day moving average of $0.48 and a two-hundred day moving average of $1.41. Harvard Bioscience has a 1-year low of $0.29 and a 1-year high of $3.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. AMH Equity Ltd raised its holdings in Harvard Bioscience by 35.5% in the first quarter. AMH Equity Ltd now owns 3,387,355 shares of the medical instruments supplier’s stock valued at $1,917,000 after acquiring an additional 887,355 shares in the last quarter. Royce & Associates LP boosted its position in shares of Harvard Bioscience by 35.4% during the 4th quarter. Royce & Associates LP now owns 1,965,114 shares of the medical instruments supplier’s stock worth $4,146,000 after purchasing an additional 513,664 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Harvard Bioscience by 11.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 200,032 shares of the medical instruments supplier’s stock worth $422,000 after buying an additional 20,026 shares in the last quarter. Nuveen LLC purchased a new position in Harvard Bioscience in the 1st quarter valued at about $79,000. Finally, JPMorgan Chase & Co. lifted its holdings in Harvard Bioscience by 285.0% in the 4th quarter. JPMorgan Chase & Co. now owns 113,591 shares of the medical instruments supplier’s stock valued at $240,000 after purchasing an additional 84,090 shares in the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.